返回 Agenda
Session 5, Part II: Panel Discussion - Next Steps
Session Chair(s)
Sara Torgal, MPHARM
Global Regulatory Policy Lead
DIA, Switzerland
Session 5, Part II: Panel Discussion - Next Steps
Speaker(s)
Panel discussion with the presence of:
Mats G. Hansson
Uppsala University, Sweden
IMI PREFER Coordinator & Senior Professor of Biomedical Ethics
Contributing Panelist
Conny Berlin, MS
Novartis Pharma AG, Switzerland
IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology
Contributing Panelist
John F. P. Bridges, PHD
Ohio State University College of Medicine, United States
Professor, Departments of Biomedical Informatics
Contributing Panelist
Laura Lee Johnson, PHD
FDA, United States
Director, Division of Biometrics III, Office of Biostatistics, OTS, CDER
Contributing Panelist
Mireille Muller, DRSC, PHD, MSC
Novartis Pharma AG, Switzerland
Regulatory Policy & Intelligence Director
Contributing Panelist
Jürgen Kübler, PHD
Quantitative Scientific Consulting, Germany
Owner
Contributing Panelist
Antonella Cardone
Cancer Patients Europe, Belgium
Director